Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16160309 | 0.84 | CES2 (0.50) | CES2CES1ALDH1A1POLBNPC1 | |
| SCHEMBL10308375 | 0.84 | PDK2 (0.46) | ALDH1A1RECQLKMT2AMAPTTP53 | |
| SCHEMBL8171481 | 0.83 | TSHR (0.59) | CES2CES1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5747509 | 0.83 | CES2 (0.54) | CES2CES1ALDH1A1POLBNPC1 | |
| SCHEMBL30529376 | 0.83 | CES2 (0.54) | CES2CES1ALDH1A1POLBNPC1 | |
| SCHEMBL24451119 | 0.82 | TAS1R3 (0.46) | CES2CES1ALDH1A1POLBKMT2A | |
| SCHEMBL30689747 | 0.82 | TAS1R3 (0.46) | CES2CES1ALDH1A1POLBKMT2A | |
| SCHEMBL9370899 | 0.82 | CES2 (0.52) | CES2CES1ALDH1A1POLBNPC1 | |
| SCHEMBL11864535 | 0.82 | ALDH1A1 (0.55) | CES2CES1ALDH1A1POLBNPC1 | |
| SCHEMBL30606489 | 0.80 | KAT6A (0.43) | CES2CES1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737486-B2 | USING ORGANIC HALIDE OR SULFUR INITIATOR; MAINTAINING PROCESS CONTROL AND UNIFORMITY | EASTMAN KODAK COMPANY | 2004-05-18 | — | — | US | claimed |
| US-20040014910-A1 | Novel polymerization process | EASTMAN KODAK COMPANY | 2004-01-22 | — | — | US | claimed |
| US-6310165-B1 | VINYL MONOMER WITH ONIUM SALT TRANSITION METAL CAYALYST | EASTMAN KODAK COMPANY | 2001-10-30 | — | — | US | claimed |
| US-6306995-B1 | CATALYTIC POLYMERIZATION WITH ONIUM CATALYSTS | EASTMAN KODAK COMPANY | 2001-10-23 | — | — | US | claimed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| CN-106349285-B | Hydroxyl acylphosphine oxide and its preparation and application | 天津久日新材料股份有限公司 | 2018-05-15 | — | — | CN | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-6229022-B1 | REACTING CARBONYL COMPOUNDS WITH HYDRAZINE, ITS HYDRATE OR SALTS IN THE PRESENCE OF SULFURIC ACID AND IODINE OR AN IODINE LIBERATING COMPOUND | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-08 | — | — | US | disclosed |
| WO-2000075094-A2 | METHOD FOR PRODUCING A HALOGENATED ACETOPHENONE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2000-12-14 | — | — | WO | disclosed |
| EP-1021416-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-26 | — | — | EP | disclosed |
| US-6093851-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998058914-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-30 | — | — | WO | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | CES2 923/4885CES1 1353/4885ALDH1A1 1702/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | CES2 4439/4885CES1 722/4885ALDH1A1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.